Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PIPE-791 in Healthy Volunteers
NCT05983939Phase 1Completed
- Sponsor
- Contineum Therapeutics
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing PIPE-791 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2023; status: completed.
02
Drugs
PIPE-791
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05983939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983939.